Estrogen receptors in hepatocellular carcinoma

Area of Science:

• Hepatology
• Endocrinology
• Oncology

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern.
• The role of estrogen receptors (ERs) in HCC development and progression is not fully understood.
• Understanding ER expression in HCC may offer new therapeutic avenues.

Purpose of the Study:

• To investigate the presence and levels of estrogen receptors in human hepatocellular carcinoma (HCC) and adjacent liver tissue.
• To correlate ER expression with clinical and pathological features of HCC.
• To assess the potential implications for hormone therapy in HCC treatment.

Main Methods:

• Estrogen receptors (ERs) were quantified in tumor and surrounding liver tissue from 30 adult HCC patients using cytosol protein assays.
• Specimens were obtained during surgical resection.
• Patients' liver conditions included cirrhosis (28) and chronic hepatitis (2).

Main Results:

• Estrogen receptors (ERs) were detected in 12 of 30 HCC samples, with values ranging from 1.4 to 9.2 fmol/mg cytosol protein.
• Measurable ERs were found in 13 of 28 cirrhotic livers (1.5–4.1 fmol/mg cytosol protein), but not in livers with chronic hepatitis.
• No correlation was observed between ER levels in HCC and serum markers (alpha-fetoprotein, CEA), HBV profiles, or tumor histology.

Conclusions:

• Estrogen receptors are present in a subset of human hepatocellular carcinoma and cirrhotic liver tissues.
• The presence of ERs in HCC suggests a potential, yet unproven, role for hormone therapy in managing this cancer.
• Further investigation is warranted to determine the clinical utility of targeting ERs in HCC treatment.